Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 16/20 | 0.64 |
| ▸ | CTSL | P07711 | 14/20 | 0.64 |
| ▸ | CTSB | P07858 | 14/20 | 0.64 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | ELOVL6 | Q9H5J4 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3796217 | 0.87 | CTSS (0.66) | CTSSCTSLCTSBCTSKELOVL6 | |
| SCHEMBL15654495 | 0.87 | CTSS (0.66) | CTSSCTSLCTSBCTSKELOVL6 | |
| SCHEMBL3801137 | 0.85 | CTSS (0.64) | CTSSCTSLCTSBCTSK | |
| SCHEMBL3803533 | 0.85 | CTSS (0.64) | CTSSCTSLCTSBCTSK | |
| SCHEMBL3801255 | 0.85 | CTSS (0.67) | CTSSCTSLCTSBCTSK | |
| SCHEMBL3800356 | 0.85 | CTSS (0.67) | CTSSCTSLCTSBCTSKGRIN1 | |
| SCHEMBL3797268 | 0.85 | CTSS (0.49) | CTSSCTSLCTSBCTSKGRIN1 | |
| SCHEMBL15654210 | 0.84 | CTSS (0.65) | CTSSCTSLCTSBCTSK | |
| SCHEMBL3805217 | 0.84 | CTSS (0.65) | CTSSCTSLCTSBCTSK | |
| SCHEMBL3801677 | 0.82 | CTSS (0.47) | CTSSCTSLCTSBCTSKGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440521-B1 | NOVEL CYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-04-30 | — | — | EP | claimed |
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | US | claimed |
| EP-2440521-B1 | NOVEL CYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-04-30 | — | — | EP | disclosed |
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | TBXA2R, ADORA1, CNR1 | CTSS 2367/4885CTSL 2122/4885CTSB 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.